Phase II study of carboplatin, irinotecan and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

BACKGROUND: We evaluated the efficacy of carboplatin, irinotecan and bevacizumab among recurrent glioblastoma (GBM) patients after prior progression on bevacizumab therapy in a phase 2, open-label, single-arm trial. METHODS: Eligible patients received carboplatin (area under the plasma curve [AUC] 4...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Reardon, David A., Desjardins, Annick, Peters, Katherine B., Vredenburgh, James J., Gururangan, Sridharan, Sampson, John H., McLendon, Roger E., Herndon, James E., Coan, April, Threatt, Stevie, Friedman, Allan H., Friedman, Henry S.
Formato: Artigo
Idioma:Inglês
Publicado: 2011
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3158844/
https://ncbi.nlm.nih.gov/pubmed/21590689
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.26188
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares